Novo Nordisk establishes new obesity research unit in Seattle

26 September 2014

Danish diabetes care giant Novo Nordisk (NOV: N) yesterday announced that the company will establish a new obesity research unit in Seattle, Washington, in the USA.

The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.

First obesity candidate Saxenda pending FDA approval

Novo Nordisk recently received a positive recommendation from the US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee regarding the New Drug Application for Saxenda, the intended brand name for liraglutide 3mg, a once-daily human GLP-1 analogue for the treatment of obesity (The Pharma Letter September 12).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK